Matinas BioPharma Holdings, Inc. (OTCMKTS:MTNB) Jump Upon News

Matinas BioPharma Holdings, Inc. (OTCMKTS:MTNB), announced the closing of an $8 million private placement equity financing.  The biopharmaceutical company sold to an aggregate 1,600,000 at a $5.00/share to investors.

BEDMINSTER, N.J., Sept. 13, 2016 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) (MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today announced the final closing of an $8.0 million private placement equity financing, which represents the full amount of the offering. The Company sold to accredited investors an aggregate of 1,600,000 Series A Preferred Shares at a purchase price of $5.00 per share.

The net proceeds to the Company from the offering were approximately $6.9 million. The net proceeds will be used for research and development activities, a new manufacturing facility and for working capital and general corporate purposes.

SternAegis Ventures, through Aegis Capital Corp., acted as the exclusive Placement Agent for the offering. Participants in the offering included members of the Board of Directors and management of the Company and affiliates of the Placement Agent.

The securities issued in the offering have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Such securities are therefore restricted in accordance with Rule 144 under the Securities Act.

This Press Release does not constitute an offer to sell or the solicitation of an offer to buy any security. The securities described herein have not been registered under the Securities Act or applicable state securities laws and may not be offered or solid in the United States or any state thereof absent registration under the Securities Act and applicable state securities laws or an applicable exemption from registration requirements.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. The Company’s proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company’s lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). The Company has an open Investigational New Drug (IND) application for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, the Company is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins and PCSK9 levels.

The Company’s lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

The average daily trading volume (ADTV) is the number of commodities traded per day on average over a specific time period.  Trading activity is tied to the liquidity of a stock.  If there is high average daily trading volume, the security can be moved easily and has high liquidity.  In contrast, if trading volume is low, the commodity will usually be less expensive due to the fact that people are not as eager to buy.  Matinas BioPharma Holdings, Inc. (OTCMKTS:MTNB)’s average trading volume is 128300.

ORIGINAL SOURCE

matinas

Are Matinas BioPharma Holdings, Inc. (OTCMKTS:MTNB) Shares Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

Matinas BioPharma Holdings, Inc. (OTCMKTS:MTNB) shares closed the most recent session at $1.24, moving from the previous open of $0.12.  This is compared to the stock’s 52-week high of 1.25 and 52-week low of 0.41.

It’s important to use market capitalization (market cap) to show the size of a company because company size is a basic characteristic in which investors are interested.  Luckily, it’s easy to calculate: Market Capitalization = Number of Shares Outstanding x Price.  For example, if a company has 10 million shares selling at $100/share, it would have a market cap of $1 billion.  Currently, Matinas BioPharma Holdings, Inc. (OTCMKTS:MTNB)’s market cap is $87130000.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information. Assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.

Related posts

Leave a Comment